Literature DB >> 17332980

Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome.

Virunya Parkpian1, Oravan Verasertniyom, Monchand Vanichapuntu, Kitti Totemchokchyakarn, Kanokrat Nantiruj, Prapaporn Pisitkul, Pantep Angchaisuksiri, Napaporn Archararit, Bupha Rachakom, Katcharin Ayurachai, Suchela Janwityanujit.   

Abstract

Antibodies to beta(2)-glycoprotein I (anti-beta(2)-GPI) have been reported to have stronger association with clinical antiphospholipid syndrome (APS) than anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC). We investigated the sensitivity and specificity of ELISA for anti-beta(2)-GPI in Thai systemic lupus erythematosus (SLE) patients with clinical features of APS and compared the results with IgG/IgM aCL and LAC to find the test with the best association. The hospital records of 151 Thai SLE patients whose sera had been sent for either IgG/IgM anticardiolipin antibodies or lupus anticoagulant testing were reviewed. Sera of patients either without complete clinical records or those with APS-related manifestations other than vascular thrombosis and pregnancy morbidity (according to the international consensus statement on preliminary classification criteria for definite APS) were excluded. For the remaining subjects (112 patients), their sera were tested for anti-beta(2)-GPI antibody, IgG and IgM anticardiolipin, and lupus anticoagulant. The sensitivity and specificity of each method were compared by using the chi-square test. Among the 112 (74.2%) SLE patients in the study, 35 (31.3%) presented with preliminary clinical criteria for APS (i.e., vascular thrombosis and pregnancy morbidity) whereas 77 (68.7%) did not. The sensitivity and specificity of anti-beta(2)-GPI determination were 57.1 and 79.2%, respectively, whereas those of IgG aCL were 25.7 and 94.8%, of IgM aCL were 5.7 and 98.7%, and of LAC were 44.8 and 77.3%, respectively. The accuracy of the four tests showed similar association with clinical APS (accuracy of test = 72.3, 73.2, 69.6, and 68.3%, respectively). Concerning the sensitivity, specificity, and difficulty of the methods, the combination of anti-beta(2)-GPI and IgG aCL tests was the best for the diagnosis of APS in Thai SLE patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332980     DOI: 10.1007/s10067-007-0566-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.

Authors:  D G Wahl; F Guillemin; E de Maistre; C Perret; T Lecompte; G Thibaut
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

3.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

4.  Analytical and clinical relationships between human IgG autoantibodies to beta 2 glycoprotein I and anticardiolipin antibodies.

Authors:  H S El-Kadi; L B Keil; V A DeBari
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

5.  A clinical study of the lupus anticoagulant.

Authors:  M A Schleider; R L Nachman; E A Jaffe; M Coleman
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

6.  beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss.

Authors:  R D Franklin; N Hollier; W H Kutteh
Journal:  Fertil Steril       Date:  2000-03       Impact factor: 7.329

7.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

8.  Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.

Authors:  J Cabiedes; A R Cabral; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1995-10       Impact factor: 4.666

9.  A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.

Authors:  T Exner; K A Rickard; H Kronenberg
Journal:  Br J Haematol       Date:  1978-09       Impact factor: 6.998

10.  Prevalence of beta 2-glycoprotein I antibody in systemic lupus erythematosus patients with beta 2-glycoprotein I dependent antiphospholipid antibodies.

Authors:  J Matsuda; N Saitoh; M Gotoh; K Gohchi; M Tsukamoto
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

View more
  4 in total

1.  Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.

Authors:  Zi-Wei Dai; Hong Wang; Wen-Juan Xu; Zhi-Hui Wang; Sheng-Qian Xu; Bin Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-07-06       Impact factor: 2.980

2.  Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Authors:  Ming-Rong Cheng; Qing Li; Tao Wan; Bing He; Jiang Han; Hou-Xiang Chen; Feng-Xiao Yang; Wei Wang; Hong-Zhi Xu; Tao Ye; Bing-Bing Zha
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

3.  Risk factors of venous thromboembolism in thai patients.

Authors:  Pantep Angchaisuksiri; Vichai Atichartakarn; Katcharin Aryurachai; Napaporn Archararit; Buppa Rachakom; Kanlayanee Atamasirikul; Arjit Tiraganjana
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

4.  DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples.

Authors:  Steven Andrew Baker; Jing Jin; Christopher Pfaffroth; Trang Vu; James L Zehnder
Journal:  Res Pract Thromb Haemost       Date:  2021-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.